Clinical trials: Metformin
- Drug or intervention Metformin
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Adult Patients With Type 2 Diabetes Mellitus
XIGDUO Extended Release (XR) Post Marketing Surveillance
This is a local, prospective, non-interventional, regulatory postmarketing surveillance study. Adult patients with type 2 diabetes mellitus who are initiating Xigduo XR as indicated by the Ministry of Food and Drug Safety (MFDS)…
- Trial name
- XigduoPMS (NCT03038789)
- Where
- 8 sites in South Korea
- Volunteers
- 623 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of sitagliptin/metformin…
- Trial name
- NCT01065766
- Testing
- Sitagliptin/metformin
- Volunteers
- 4,065 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Malignancy Meta Analysis for BRL49653
Observational analyses of data from population registeries have suggested that metformin may be associated with a decreased prevalence of malignancy.
- Trial name
- NCT01195259
- Testing
- allocation of treatment with metformin or rosiglitazone
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM
The purpose of this study is to evaluate the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects with Type 2 diabetes mellitus (T2DM) following oral administration of Saxagliptin and…
- Trial name
- NCT01525225
- Testing
- Metformin immediate release (IR), Saxagliptin, Metformin IR
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
Primary Objective: To demonstrate safety of 14-day repeated lixisenatide doses with 3 ascending doses as compared to placebo in pediatric patients with T2DM.
- Trial name
- NCT02803918
- Testing
- Lixisenatide (AVE0010), Basal Insulin, Metformin
- Where
- 11 sites in United States, Mauritius and 4 more
- Volunteers
- 23 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the pharmacokinetics (blood levels) and pharmacodynamics (the action or effects a drug has on the body) of canagliflozin in children and adolescents with type 2 diabetes mellitus aged 10…
- Trial name
- NCT02000700
- Testing
- Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg
- Where
- 17 sites in United States, Brazil
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes, Diabetes Mellitus Type 2
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate the efficacy, safety, and tolerability of once-daily subcutaneous (SC) injections of NNC0090-2746 for 12 weeks, as an adjunct…
- Trial name
- NCT02205528
- Testing
- Liraglutide, Metformin, NNC0090-2746
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of insulin detemir versus insulin Neutral Protamine Hagedorn (NPH) in combination with the maximum tolerated dose of metformin and…
- Trial name
- iDEAt2 (NCT02131272)
- Testing
- Insulin detemir, Insulin NPH, Diet/exercise
- Where
- 82 sites in United States, Argentina and 22 more
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Characteristics of Empagliflozin Initiators
Empagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, was launched in the United Kingdom (UK) in August 2014. It can be expected that patients initiating empagliflozin may differ in their characteristics from…
- Trial name
- NCT03050619
- Testing
- Empagliflozin, Other SGLT2 inhibitors, Other non-insulin GLDs
- Where
- Germany
- Volunteers
- 31,908 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Fast-acting insulin aspart (faster aspart) will be tested to see how well it works and if it is safe. The study compares 2 medicines for type 1 and type 2 diabetes - faster aspart (a new medicine) and insulin aspart (a medicine…
- Trial name
- NCT04588259
- Testing
- Faster aspart, Insulin aspart, Insulin degludec
- Where
- 40 sites in China, Hong Kong
- Volunteers
- 331 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy medicine.
- Trial name
- PIONEER TEENS (NCT04596631)
- Testing
- Oral semaglutide
- Where
- 97 sites in United States, Australia and 20 more
- Volunteers
- 132 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents
The purpose of this research was to assess the absolute and relative incidence of acute pancreatitis in persons initiating exenatide compared with persons initiating a different antidiabetic agent, and secondarily, persons…
- Trial name
- NCT01077323
- Testing
- exenatide, Other antidiabetic therapies, No diabetes therapy
- Where
- United States
- Volunteers
- 363,766 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)
The primary objective of this study is to obtain safety information on the use of sitagliptin phosphate/metformin hydrochloride (HCl) (JANUMET®) from endocrinologists, diabetologists, internists, and general practitioners.
- Trial name
- NCT01357148
- Testing
- Sitagliptin Phosphate/Metformin HCl (JANUMET®)
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice
The study is designed as non interventional to collect data on the safety especially, severe hypoglycemia or documented symptomatic hypoglycemic episodes and effectiveness of acarbose/metformin fixed-dose combination under…
- Trial name
- GLORY (NCT01915264)
- Testing
- Acarbose/Metformin (Glucobay M, BAY81-9783)
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
This study evaluated the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin.
- Trial name
- NCT04029480
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Insulin
- Where
- 104 sites in United States, Belgium and 20 more
- Volunteers
- 166 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Prospective, Observational Study to Assess and Evaluate the Use of Glucophage XR Therapy in the Management of Patients With Type 2 Diabetes
This was an observational, prospective, multicentric study conducted in a cohort of subjects with type 2 diabetes and prescribed with Glucophage XR therapy from hospitals or clinics in Hong Kong, Indonesia, Korea, Malaysia…
- Trial name
- NCT01117103
- Where
- Singapore
- Volunteers
- 3,592 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Diabetes Mellitus, Non-Insulin-Dependent
A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.
The purpose of this clinical research study is to see if Glucovance, a medication currently approved for use in adults with type 2 diabetes, can control type 2 diabetes safely and effectively in children 9 to 16 years of age.
- Trial name
- NCT00035542
- Testing
- Glucovance (metformin HCl/glyburide), metformin HCl, glyburide
- Where
- 50 sites in United States
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)
The purpose of this study is to assess: 1. the safety and tolerability of two sitagliptin 50 mg/metformin 1000 mg XR tablets in pediatric participants with type 2 diabetes mellitus (T2DM), aged 10 to 17 years 2.
- Trial name
- NCT01557504
- Testing
- Sitagliptin/metformin XR, Metformin, Thyroid hormone
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"
The purpose of this survey is to evaluate the long-term safety and efficacy of the alogliptin and metformin hydrochloride combination tablet in type 2 diabetes mellitus patients with renal impairment (mild), hepatic impairment…
- Trial name
- NCT03555565
- Testing
- Alogliptin and Metformin hydrochloride
- Where
- Japan
- Volunteers
- 1,026 people
- Sponsor
- Takeda
Healthy
Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers
Study to assess bioequivalence of a 2.5 mg linagliptin / 850 mg metformin fixed dose combination (FDC) tablet compared to single tablets of linagliptin 2.5 mg and metformin 850 mg administered together
- Trial name
- NCT02220647
- Testing
- Linagliptin/Metformin FDC, Linagliptin, Metformin
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim